Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The present study was performed to investigate the prognostic value of plasma interleukin-6 (IL-6) concentrations and promoter polymorphisms of the IL-6 gene in patients with acute myocardial infarction treated with thrombolysis. Two hundred and eight patients with myocardial infarction treated with thrombolysis were included and followed for 2-5 years. Plasma concentrations of IL-6 were measured at admission and 48 h after admission. Genotyping for the -174 G > C and -572 G > C IL-6 polymorphisms was performed. Patients who died of cardiovascular causes or suffered a new myocardial infarction during follow-up had increased plasma concentrations of IL-6 at admission (P < 0.002) and at 48 h after admission (P < 0.05) compared with patients who had an uneventful course. IL-6 levels above the median at admission were independently associated with a worse prognosis. No associations were found between IL-6 levels and the promoter polymorphisms. The -174 G > C polymorphism was not associated with cardiovascular death or a new myocardial infarction, whereas the -572 G > C polymorphism showed a borderline significant increase in risk (P = 0.05) in univariate analysis. In conclusion, the early IL-6 response during myocardial infarction is associated with prognosis in patients with Q-wave myocardial infarction, whereas no associations were found between IL-6 genotype and phenotype.

Original publication

DOI

10.1016/j.atherosclerosis.2004.01.019

Type

Journal article

Journal

Atherosclerosis

Publication Date

05/2004

Volume

174

Pages

157 - 163

Keywords

Aged, Biomarkers, C-Reactive Protein, Cohort Studies, Confidence Intervals, Creatine Kinase, Female, Genetic Markers, Heart Function Tests, Hemodynamics, Humans, Interleukin-6, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction, Polymorphism, Genetic, Probability, Prognosis, Promoter Regions, Genetic, Proportional Hazards Models, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Rate, Thrombolytic Therapy